


Champalimaud's "TIL (Tumor Infiltrating Lymphocytes) for the Treatment of Patients with Solid Cancer – Experts on Future Perspectives"



24 - 25 April 2024
Lisbon, Portugal
Course no. 6989



Biotechnology

Target group

TIL for the Treatment of Patients with Solid Cancer – Experts Future Perspectives workshop

Experts from science, industry and authorities involved in development, regulation and marketing of TIL or other T-cell based (transgenic) therapeutic products; Physicians involved in cell-based immunotherapy and immunotherapy in general; Individuals involved in TIL manufacturing and other transgenic immune cell products. Scientists engaged in the development of new cell therapeutic platforms.;Interested individuals who may profit from concept and process oriented inclusive discussions addressing immune cell biology and regulatory hurdles.

Personalized T-cell therapy has now reached the solid tumor field as a first-of-its-kind immunotherapy for patients with melanoma with an approval granted by the FDA on February 17th 2024!

In cooperation with



**Champalimaud
Foundation**





Objectives of the workshop

To present and discuss scientific expertise in the development, manufacturing, analysis, quality assurance, distribution and clinical use of advanced therapy medicinal products (ATMPs), knowledge sharing and to support interested stakeholders in cell therapy and regulatory processes.

We offer a discussion platform for:

- Active participation in an interdisciplinary workshop,
- individual networking with enthusiastic, like-minded colleagues,
- workshop and training of the highest quality.

Goals of the "TIL for the Treatment of Patients with Solid Cancer – Experts Future Perspectives" workshop:

The 1,5-day workshop includes a public overview presentation provided by internationally renowned experts and key opinion leaders in the field of cell therapy for patients with cancer: Michael T Lotze, UPMC, USA and Markus Maeurer, University of Mainz, Germany and Champalimaud Foundation, Portugal.

The remaining closed part of the workshop will provide an expert view on TIL as a therapeutic treatment option for patients with different tumor entities. Speakers will share state of the art background knowledge from the research & development of biologically and clinically relevant therapeutics, including updates on current TIL protocols and trials, the increased recognition of "non-conventional" T-cells in cell therapy, the biological significance of molecular mapping of the raw product, high-content immuno-monitoring, personalized vaccine trials and transgenic immune cell products. The seminar will focus on regulatory (GMP) and quality aspects of the starting cell, isolation, expansion of T-cells from different cancer types, ex-vivo T-cell education with defined tumor-antigens, manufacturing of clinical trial material and the specification of the final release cell product. Round table discussions will provide discussions about regulatory and scientific topics in an interactive, open and inclusive manner.

Including onsite facility tours:

All participants of both workshops will have the possibility of joining two separate facility tours through the new clinical building of the Champalimaud Centre of the Unknown and the newly installed GMP manufacturing facility, which is currently in the qualification phase.

Course leaders



**Prof. Markus Maeurer, MD, PhD, FRCP (London)
Champalimaud Foundation**

Markus J Maeurer received his Medical degree from the Johannes Gutenberg University of Mainz, Germany in 1989. He has been a Research Fellow at the Department of Surgical Oncology, University of Pittsburgh, USA, Assist. Prof of Surgical Oncology and Immunotherapy at UPMC, Pittsburgh, PA, USA. (1999) full Professor of Microbiology and Infectious Diseases at the University of Mainz and Head of the diagnostic Laboratory at the Department of Medical Microbiology (2005) Professor of Infectious Diseases, particularly Clinical Immunology, at the MTC (Microbiology, Tumor Biology Center) of the Karolinska Institute. He then served as head of the division of Therapeutic Immunology at the Karolinska Institute and as Senior Physician of the Center for allogeneic stem cell transplantation, CAST, Karolinska Hospital from 2012 to 2017.

Dr. Maeurer is head of immunotherapy / ImmunoSurgery at the Champalimaud Foundation, Lisbon, and Full Professor at the I Medical Clinic of the University of Mainz, Germany. He has published more than 310 scientific articles (28 of which are in the LANCET series) he created 9 patents, and he serves as a reviewer for several international grant agencies, governments and at several high impact journals as editor or reviewer. He is an advisor for the Bill and Melinda Gates Foundation, for the UK Parliament and the Italian Government. He is a Fellow of the Royal Chamber of Physicians, London, and initiated with Sir Alimuddin Zumla (UCL, UK) the consortium against cancer and infectious diseases with a particular focus on COVID-19 (<https://www.fchampalimaud.org/covid19>). He is responsible for governing the newly established GMP facility (for GMP and non-GMOs) at the Champalimaud Foundation.



**Michael T. Lotze, MD
UPMC**

Michael T. Lotze, M.D. served as Chief Cellular Therapy Officer of Nurix and previously as Chief Scientific Officer at Iovance. He is a leading clinician scientist with more than 40 years of experience in immunology and clinical medicine, dedicating his efforts to the advancement of translational research, particularly in immunotherapy for cancer including dendritic cell, T cell, and cytokine therapies. Dr. Lotze is the co-inventor of multiple patents in dendritic cell vaccines and antigen discovery, and tumor infiltrating lymphocyte therapy. He previously held leadership roles in the biopharmaceutical industry as vice president of research at GlaxoSmithKline. Currently, Dr. Lotze serves as professor of surgery, immunology, and bioengineering, and director for Damage Associated Molecular Pattern Molecule (DAMP) Laboratories at the University of Pittsburgh Medical Center

Hillman Cancer Center. He is also senior advisor for the Immune Transplant and Therapy Center within the University of Pittsburgh Medical Center Enterprises and serves as associate editor of the Journal of Immunotherapy. Over the course of his career, he has authored more than 500 publications and several books. Dr. Lotze holds an M.D. from Northwestern University and completed his postdoctoral training as a scientist at the National Cancer Institute under Dr. Steven Rosenberg.



TIL FOR THE TREATMENT OF PATIENTS WITH SOLID CANCER – EXPERTS ON FUTURE PERSPECTIVES

Program

Wednesday, 24 April 2024 09:00 - 17:30 h

09:00 - 11:15 h

Welcome address

Leonor Belez, João Silveira Botelho, Markus Maeurer
Champalimaud Foundation

The Champalimaud TIL program

Markus Maeurer, Champalimaud Foundation, Lisbon,
Portugal

Cellular immunotherapy and TIL – history of development and a future foretold

Michael T. Lotze, Departments of Surgery, Immunology, and
Bioengineering, University of Pittsburgh Medical Center,
Pittsburgh, USA

Moderated discussion

Farewell for public participants and coffee break

Closed Expert Workshop

11:15 - 17:30 h

Welcome address to the participants of the workshop

Markus Maeurer, Champalimaud Foundation, Lisbon,
Portugal

Losing it all – the case for functional MHC expression testing: prerequisites for cell therapy

Barbara Seliger, Translational Immunology MHB Fontane
Brandenburg, Brandenburg, Germany

TCR gamma-delta – T-cells for immunotherapy of epithelial cancers

Dieter Kabelitz, UKSH Institute Immunology, University of
Kiel, Kiel, Germany

Moderated discussion

Lunch break kindly sponsored by

Lonza

13:00 - 14:30 h

Presentation of the Lonza Cocoon System

Clonal neoantigens as key targets for TIL therapy in non-small cell lung cancer

Sergio Quezada, University College London and Achilles
London, UK

Clonotypes dynamic and specificity as correlates of efficacy of TIL therapy

Alexandre Harari, Ludwig Institute for Cancer Research,
Lausanne, Switzerland

Moderated discussion

Coffee break

The other side of T-cell therapy: private mutations - peptide cancer vaccination

Saskia Biskup, CeGaT & University of Tuebingen, Tuebingen,
Germany

Interaction of TIL with the TME – good or bad?

Elfriede Noessner, Helmholtz Center, Munich, Germany

Moderated discussion

Social Program TIL Expert Workshop

18:00 h

Tejo sightseeing walk to places of interest, e.g. Hieronymites
Monastery (Mosteiro dos Jeronimos) and Tower of Belem.

Networking dinner at Darwin's Cafe, Drinks & Food



Thursday, 25 April 2024

Closed Expert Workshop 08:45 - 18:30 h

Introduction

Markus Maeurer and Carlos Carvalho
Champalimaud Foundation, Lisbon, Portugal

TIL expansion for the treatment of patients with epithelial cancer

Markus Maeurer, Champalimaud Foundation, Lisbon, PT

TIL – treatment for patients with melanoma clinical experience and future directions

Guy Ben-Betzalel, Ella Lemelbaum Institute for Immuno-Oncology. Sheba Clinic, Tel HaShomer, Israel

Moderated discussion

Coffee break

Managing Exhaustion and T-cell fitness: Lessons from CAR-T-cell therapies

Orit Itzhaki, Sheba-Clinical Center, Tel HaShomer, Israel

A tale of tribulations and trials: developing a cell therapy program in Europe

Lana Kandalaft, Chief of Service of the Center of Experimental Therapeutics Dept of Oncology, CHUV-UNIL Assoc.Dir of clinical translation/Ludwig Institute for Cancer Research, Lausanne, Switzerland

Moderated discussion

Lunch break kindly sponsored by
Wilson Wolf Corporation

12:00 - 13:30h

Presentation of G-Rex, Cell Ready System, Wilson Wolf Corp.

Regulation of 'Tumor Infiltrating Lymphocytes' in Europe

N.N., CAT/INFARMED speaker inquired

Cell therapies come of age – balance of efficacy and safety: lessons from CAR-T-cell trials

Michael Bachmann, Helmholtz-Zentrum Dresden-Rossendorf (HZDR) and German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany

Moderated panel discussion

Coffee break and farewell Address to Participants of Champalimaud's Closed Expert Workshop

Common Facility Introduction

15:30 - 16:30 h

Opening ceremony and welcome address

Markus Maeurer, Cristina Afonso, Joaquim Teixeira, Magdalena Obarzanek-Fojt, Hans-Georg Eckert

From Vision to reality: installation of GMP manufacturing facility at Champalimaud Foundation – concept, construction, manufacturing start-up

Cristina Afonso, Nuno Pereira, Joaquim Texeira, Champalimaud Foundation & Peter Christian Rehm, Hans-Georg Eckert, Syntegon/Valicare

The Champalimaud Center of the unknown – history of a modern hospital facility

Joaquim Teixeira and Carlos Carvalho, Champalimaud Foundation

Facility/Hospital Tours

16:30 - 18:30 h

GMP Manufacturing Facility tour and Champalimaud Centre for the Unknown Hospital Round Tour

Program is subject to change



TIL regulatory talks: Open for participants of the ATMP Regulation & Manufacturing Basics Workshop

Registration by fax +49 6131 97 69 69 or by email apv@apv-mainz.de



Location

Champalimaud Foundation and Botton-
Champalimaud Pancreatic Cancer
Centre, Lisbon Portugal
Avenida Brasília
1400-038 Lisboa
Portugal
phone + 351 210 480 200
mail info@fundacaochampalimaud.pt
web www.fchampalimaud.org

Registration fee

Separated tickets: 6989 TIL (24-25.4.)
Industry 1590 EUR
Authority/University 795 EUR
Students* 150 EUR

Combined ticket TIL and ATMP

(24-26.4.) (6991):
Industry 2490 EUR
Authority/University 1245 EUR
Students* 250 EUR

Registration

APV-Geschäftsstelle
Kurfürstenstraße 59
55118 Mainz/Germany
Phone: 0049 6131 97 69 0
E-mail: apv@apv-mainz.de
Web: www.apv-mainz.de

(free of VAT according to § 4,22 UStG)
Coffee breaks, luncheons, dinner and
electronic proceedings included.
* Limited places for full time students
available; written evidence must be
submitted.

Hotel reservation

Please book your hotel yourself.
We recommend using official hotel
booking platforms such as
booking.com or hrs.com.

Date

Course no.: 6989 (TIL)
from 24 April 2024 09:00 h
to 25 April 2024 18:30 h

TIL Expert Workshop, 24 - 25 April 2024, Lisbon, Portugal, Course no.: 6989

Registration

As soon as you have found a seminar of your interest,
it is very easy to register for it via fax, e-mail or online.
We will process your registration promptly and
certainly are available for any questions that may arise.

Registration confirmation

After your registration has been successfully processed,
you will receive a confirmation.

Before the event

A few days before the event starts, you will receive
important information about the seminar, such as
time, date, addresses etc.

After the event

You will receive a certificate confirming your
participation. Furthermore, we would like to ask you
to fill-in our evaluation sheet to make sure we get
better every time.

Follow-up

After the event, we are open to receive any suggestions
and critique that might arise during the seminar and will
certainly help you with further questions you may have.

Declaration of consent in respect of data protec- tion

By registering for this seminar, I agree that
the APV uses my data for the purpose of
processing the order and provides me with all
relevant information.

I also agree that APV may contact me for the
purpose of exchanging similar information by
email or post.

Your data will not be shared with third parties. You
have a right of withdrawal at any time without
giving reasons.

All other information can be found in our privacy policy
(www.apv-mainz.de/en/imprint/data-protection-statement/).

Arbeitsgemeinschaft für Pharmazeutische
Verfahrenstechnik e.V.
Gemeinnütziger wissenschaftlicher Verein
International Association for Pharmaceutical Technology

www.apv-mainz.de/en

Title, first name, last name *

Company name *

Street/no. or P.O. box *

Location

Zip-code and city *

Phone

E-mail-address participant *

Order no. and/or billing address

Pay via invoice

pay via credit card (Visa, MasterCard, Amex)

(You will receive further payment information with the invoice)

Select ticket*: TIL Expert Workshop (6989)

Combi 6991: TIL Expert Workshop (6989) + ATMP Basics Workshop (6990)

Date *

Signature *

* *Mandatory*

APV-Geschäftsstelle
Phone: 0049 6131 97 69 0

Kurfürstenstraße 59
Fax: 0049 6131 97 69 69

55118 Mainz/Germany
E-mail apv@apv-mainz.de